BOT 0.68% 37.3¢ botanix pharmaceuticals ltd

If you want to refute his point, read some insurance plan PDS's,...

  1. 20 Posts.
    lightbulb Created with Sketch. 5
    If you want to refute his point, read some insurance plan PDS's, from one of the significant coverers, where sofdra is listed as a t1/t2 covered product and post them. The disclaimer "being everywhere on every forecast" doesn't magically make the disclaimer redundant. It's there to state the information shared has not become reality yet and isn't guaranteed to become reality.
    What jcurve has posted here recently was entirely fair, and if it reminded people insurance isn't a done deal yet, that's a good thing. Call it a bit of devil's advocacy, after all he put more effort into his research than those did in replying to him with webinar forecasts.
    Grainofsand's response was far more reasonable. As about the largest insurers, remind readers of the shear number of plans on the market making it difficult to gauge coverage for the product.


 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.